Granted Patent
B2
US 12,234,453 · App. 18/329,541 · Granted Feb 25, 2025
Regulation of transcription through CTCF loop anchors
Inventors:
Jurian Schuijers (Somerville, MA); Abraham S. Weintraub (Cambridge, MA); John C. Manteiga (Boston, MA); Richard A. Young (Boston, MA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are methods of altering expression of a gene with a promoter region CTCF binding site. Also disclosed are compositions and methods useful for treating a disease or condition involving over-expression or under-expression of a gene with a promoter region CTCF binding site. Further disclosed are cells and non-human animals with modified a promoter region CTCF binding site, as well as methods for screening for compounds that can modify the expression of a gene with a promoter region CTCF binding site.
Claims (25)
1. A method for methylating a promoter region CTCF binding site of a gene in a cell comprising introducing into the cell:
(a) a fusion protein comprising a catalytically inactive Cas9 operably linked to at least one DNA methyltransferase, or a nucleic acid encoding the fusion protein; and
(b) a nucleic acid comprising one or more guide sequences homologous to a sequence, wherein the sequence is (i) in the promoter region CTCF binding site or (ii) within a region of 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides upstream or downstream of the promoter region CTCF binding site, thereby methylating the promoter region CTCF binding site.
2. The method of claim 1 , wherein the gene is an oncogene.
3. The method of claim 1 , wherein the gene is selected from the group consisting of MYC, TGIF1, VEGFAI, RUNX1, CDK6, BCL2L1, PIM1, and CSNK1A1.
4. The method of claim 1 , wherein the gene is MYC.
5. The method of claim 1 , wherein the at least one DNA methyltransferase is selected from the group consisting of DNA (cytosine-5)-methyltransferase 3A (DMNT3A) or a portion thereof, DMNT3L or a portion thereof, and a combination thereof.
6. The method of claim 1 , wherein the fusion protein comprises dCas9 operably linked to DNMT3A-L, with or without a 5′NLS.
7. The method of claim 1 , wherein the sequence is in the promoter region CTCF binding site.
8. The method of claim 1 , wherein the sequence is within a region 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides upstream or downstream of the promoter region CTCF binding site.
9. The method of claim 1 , comprising introducing into the cell the nucleic acid encoding the fusion protein.
10. A method of decreasing expression of a gene having a promoter region CTCF binding site in a cell, comprising introducing into the cell:
(a) a fusion protein comprising a catalytically inactive Cas9 operably linked to at least one DNA methyltransferase, or a nucleic acid encoding the fusion protein; and
(b) a nucleic acid comprising one or more guide sequences homologous to a sequence wherein the sequence is (i) in the promoter region CTCF binding site or (ii) within a region of 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides upstream or downstream of the promoter region CTCF binding site, thereby decreasing expression of the gene,
wherein expression of the gene is decreased compared to expression of the gene in a cell not introduced with (a) and (b).
11. The method of claim 10 , wherein the introducing decreases binding of a CTCF protein to the promoter region CTCF binding site, wherein decreased binding is compared to binding of a CTCF protein to the promoter region CTCF binding site in the cell not introduced with (a) and (b).
12. The method of claim 10 , wherein the introducing increases the degree of methylation of the promoter region CTCF binding site, wherein the increased degree of methylation is compared to the degree of methylation of the promoter region CTCF binding site in the cell not introduced with (a) and (b).
13. The method of claim 10 , wherein the gene is an oncogene.
14. The method of claim 10 , wherein the gene is selected from the group consisting of MYC, TGIF1, VEGFAI, RUNX1, CDK6, BCL2L1, PIM1, and CSNK1A1.
15. The method of claim 10 , wherein the gene is MYC.
16. The method of claim 10 , wherein the at least one DNA methyltransferase is selected from the group consisting of DMNT3A or a portion thereof, DMNT3L or a portion thereof, and a combination thereof.
17. The method of claim 10 , wherein the fusion protein comprises dCas9 operably linked to DNMT3A-L, with or without a 5′NLS.
18. The method of claim 10 , wherein the sequence is in the promoter region CTCF binding site.
19. The method of claim 10 , wherein the sequence is within a region 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides upstream or downstream of the promoter region CTCF binding site.
20. The method of claim 10 , comprising introducing into the cell the nucleic acid encoding the fusion protein.
Assignments (2)
SECURITY INTEREST
Recorded Feb 10, 2025
From: OMEGA THERAPEUTICS, INC.
To: PIONEERING MEDICINES 08- B, INC.
Reel/Frame 070167/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 5, 2023
From: SCHUIJERS, JURIAN; WEINTRAUB, ABRAHAM S.; MANTEIGA, JOHN; YOUNG, RICHARD A.
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 064793/0450 →
Continuity (3)
Division
16469131
Provisional Application
62433234
· Dec 12, 2016
References Cited (201)
US 6780986B1
· Heintz et al.
· 2004
[cited by applicant]
US 8513207B2
· Brown
· 2013
[cited by applicant]
US 9801877B2
· Yao et al.
· 2017
[cited by applicant]
US 20080311039A1
· Bonavida et al.
· 2008
[cited by applicant]
US 20090082470A1
· Farjo
· 2009
[cited by applicant]
US 20150353885A1
· Sourdive
· 2015
[cited by applicant]
US 20150376612A1
· Lee et al.
· 2015
[cited by applicant]
US 20160186208A1
· Jaenisch et al.
· 2016
[cited by applicant]
US 20170014449A1
· Bangera et al.
· 2017
[cited by applicant]
US 20170130247A1
· Dowen et al.
· 2017
[cited by applicant]
US 20190127713A1
· Gersbach
· 2019
[cited by applicant]
US 20200149039A1
· Schuijers et al.
· 2020
[cited by applicant]
US 20240263184A1
· Young et al.
· 2024
[cited by applicant]
EP 3382018A1
· 2018
[cited by applicant]
WO WO2006025802A1
· 2006
[cited by applicant]
WO WO2009146033A2
· 2009
[cited by applicant]
WO WO2012019168A3
· 2012
[cited by applicant]
WO WO2013176772A1
· 2013
[cited by applicant]
WO WO2014071247A1
· 2014
[cited by applicant]
WO WO2014172470A2
· 2014
[cited by applicant]
WO WO2015033293A1
· 2015
[cited by applicant]
WO WO2015038892A1
· 2015
[cited by applicant]
WO WO2015191780A2
· 2015
[cited by applicant]
WO WO2015196128A2
· 2015
[cited by applicant]
WO WO2016063264A1
· 2016
[cited by applicant]
WO WO2016022363A3
· 2016
[cited by applicant]
WO WO2016081798A1
· 2016
[cited by applicant]
WO WO2016070037A3
· 2016
[cited by applicant]
WO WO2016103233A2
· 2016
[cited by applicant]
WO WO2016115326A1
· 2016
[cited by applicant]
WO WO2016073990A3
· 2016
[cited by applicant]
WO WO2016130600A2
· 2016
[cited by applicant]
WO WO2016154330A1
· 2016
[cited by applicant]
WO WO2016164356A1
· 2016
[cited by applicant]
WO WO2016174250A1
· 2016
[cited by applicant]
WO WO2016130600A9
· 2016
[cited by applicant]
WO WO2017031370A1
· 2017
[cited by applicant]
WO WO2017040793A1
· 2017
[cited by applicant]
WO WO2017011710A3
· 2017
[cited by applicant]
WO WO2017064546A1
· 2017
[cited by applicant]
WO WO2017106290A1
· 2017
[cited by applicant]
WO WO2017143042A3
· 2017
[cited by applicant]
WO WO2017208247A1
· 2017
[cited by applicant]
WO WO2018035495A1
· 2018
[cited by applicant]
WO WO2018049073A1
· 2018
[cited by applicant]
WO WO2018049075A1
· 2018
[cited by applicant]
WO WO2018049077A1
· 2018
[cited by applicant]
WO WO2018049079A1
· 2018
[cited by applicant]
WO WO2018111944A1
· 2018
[cited by applicant]
WO WO2018129544A1
· 2018
[cited by applicant]
WO WO2018204764A1
· 2018
[cited by applicant]
WO WO2019036430A1
· 2019
[cited by applicant]
WO WO2019071054A1
· 2019
[cited by applicant]
Amabile, et al., “Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing,” Cell, 167:219-232 (2016).
[cited by applicant]
Banani et al., “Biomolecular condensates: organizers of cellular biochemistry,” Nature Reviews Molecular Cell Biology, vol. 18, No. 5, pp. 285-298 (2017).
[cited by applicant]
Barrera, L. et al., “Survey of variation in human transcription factors reveals prevalent DNA binding changes,” Science, 351 (6280):1450-1454 (2016).
[cited by applicant]
Beagan JA, et al., “YY1 and CTCF orchestrate a 3D chromatin looping switch during early neural lineage commitment,”
[cited by applicant]
Bell, A.C., et al., “Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene,” Nature 405, 482-485 (2000).
[cited by applicant]
Bonavida, “Therapeutic YY1 inhibitors in cancer: ALL in ONE,”
[cited by applicant]
Brunk, et al., “Regulated demethylation of the myoddistal enhancer during skeletal myogenesis,” Developmental biology, 177.2: 490-503 (1996).
[cited by applicant]
Chen, W.G., et al., “Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2,” Science 302, 885-889 (2003).
[cited by applicant]
Cho, et al., “Antisense Transcription and Short Article Heterochromatin at the DMI CTG Repeats Are Constrained by CTCF,” Molecular Cell, vol. 20, pp. 483-489 (2005).
[cited by applicant]
Choudhury, et al., “CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter,” Oncotarget, vol. 7, No. 29, pp. 46545-46556 (published Jun. 23, 2016).
[cited by applicant]
Cong, et al., “Multiplex Genome Engineering Using CRISPR/Cas Systems” Science, vol. 339, pp. 819-823 (2013).
[cited by applicant]
De Groote, et al. “Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes,” Nucleic Acids Res, vol. 40, No. 21, pp. 10596-10613 (2012).
[cited by applicant]
De Souza, et al., “DNA methylation profiling in human Huntington's disease brain,” Human Molecular Genetics, vol. 25, No. 10, pp. 2013-2030 (2016).
[cited by applicant]
De Wit, et al., “CTCF Binding Polarity Determines Chromatin Looping,” Molecular Cell, vol. 60. No. 4, pp. 676-684 (2015).
[cited by applicant]
Deng, et al., “Controlling Long-Range Genomic Interactions at a Native Locus by Targeted Tethering of a Looping Factor,” Cell, vol. 149, pp. 1233-1244 (2012).
[cited by applicant]
Dowen, J. et al., “Control of Cell Identity Genes Occurs in Insulated Neighborhoods in Mammalian Chromosomes,” Cell, 159:374-387 (2014).
[cited by applicant]
Dávalos-Salas, et al., “Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter,” BMC cancer, 11.1, 1-11 (2011).
[cited by applicant]
Ecker, et al., “Genomics: ENCODE explained,” Nature, Sep. 6; vol. 489 (7414) pp. 52-55 (2012).
[cited by applicant]
Extended European Search Report for Application No. 17849560.2 dated Mar. 31, 2020.
[cited by applicant]
Filippova, et al., “Tumor-associated Zinc Finger Mutations in the CTCF Transcription Factor Selectively Alter Its DNA-binding Specificity,” Cancer Research, 62, 48-52 (2002).
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/469,131 dated Feb. 3, 2023.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/476,868 dated Feb. 6, 2023.
[cited by applicant]
Flavahan, et al., “Insulator dysfunction and oncogene activation in IDH mutant gliomas,” Nature, vol. 529, No. 7584, pp. 110-114 (2015).
[cited by applicant]
Guo et al., “YY1 Target DB: an integral information resource for Yin Yang 1 target loci,” Database, vol. pp. 1-10 (2013).
[cited by applicant]
Guo, C. et al., “CTCF Binding Elements Mediate Control of V(D)J Recombination,” Nature, 477(7365):424-430 (2011).
[cited by applicant]
Herold, M. et al., “CTCF: insights into insulator function during development,” Development, 139:1045-1057 (2012).
[cited by applicant]
Hnisz, D. et al., “Activation of proto-oncogenes by disruption of chromosome neighborhoods,” Science, 351(6280):1454-1458 (2016).
[cited by applicant]
Hnisz, D. et al., “Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers,” Molecular Cell, 58:362-370 (2015).
[cited by applicant]
Hnisz, D. et al., “Super-Enhancers in the Control of Cell Identity and Disease,” Cell, 155:934-947 (2013).
[cited by applicant]
Hsu, “Completion of a Programmable DNA-Binding Small Molecule Library,” Thesis, California Institute of Technology, retrieved from thesis.library.caltech.edu/4398, 153 pages (2008).
[cited by applicant]
Hsu, Carey Frank, “Completion of a Programmable DNA-Binding Small Molecule Library,” Thesis, California Institute of Technology [retrieved Nov. 22, 2017], from the internet: https://thesis.library.caltech.edu/4398/ (Oct…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/047674, issued Feb. 19, 2019.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/050553, issued Mar. 12, 2019.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/065918, issued Jun. 18, 2019.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2017/050553, dated Jan. 30, 2018.
[cited by applicant]
International Search Report for International Application No. PCT/US2017/47674, dated Jan. 4, 2018.
[cited by applicant]
International Search Report for International Application No. PCT/US2017/065918, dated Apr. 30, 2018.
[cited by applicant]
International Search Report for PCT/US2017/50553 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 6 pages (Jan. 30, 2018).
[cited by applicant]
International Search Report for PCT/US2017/50556 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 5 pages (Dec. 26, 2017).
[cited by applicant]
International Search Report for PCT/US2017/50558 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 5 pages (Dec. 18, 2017).
[cited by applicant]
International Search Report for PCT/US2017/50561 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 5 pages (Dec. 18, 2017).
[cited by applicant]
International Search Report issued in PCT/US2018/013003 dated Jun. 1, 2018.
[cited by applicant]
Ishimaru, Naoki, et al., “Differential epigenetic regulation of BDNF and NT-3 genes by trichostatin A and 5-aza-2′-deoxycytidine in Neuro-2a cells,” Biochemical and biophysical research communications, 394.1: 173-177 (2…
[cited by applicant]
Issad, et al., “O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity,” Trends in Endocrinology and Metabolism, 19, 10, 380-389 (2008).
[cited by applicant]
Ji, X. et al., “3D Chromosome Regulatory Landscape of Human Pluripotent Cells,” Cell Stem Cell, 18:262-275 (2016).
[cited by applicant]
Ji, X. et al., “Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions,” PNAS, 112(12):3841-3846 (2015).
[cited by applicant]
Jinek, et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,” Science, vol. 337, pp. 816-821 (2012).
[cited by applicant]
Kang, J.Y., et al., “Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression,” Oncogene 34, 5677-5684 (2015).
[cited by applicant]
Kearns, et al., “Functional annotation of native enhancers with a Cas9-histone demethylase fusion” Nature Methods, vol. 12, No. 5, pp. 401-403 (2015).
[cited by applicant]
Kim, et al., “Genome-wide target specificities of CRISPR RNA-guided programmable deaminases,” Nat Biotechnol, vol. 35, pp. 475-480 (2017).
[cited by applicant]
Kim, S., et al., “CTCF as a multifunctional protein in genome regulation and gene expression,”
[cited by applicant]
Koferle, et al., “Brave new epigenomes: the dawn of epigenetic engineering,” Genome Medicine, vol. 7, No. 59, pp. 1-3 (2015).
[cited by applicant]
Komor, et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage,” Nature, vol. 533, pp. 420-424, Supplement (2016).
[cited by applicant]
Krylov, et al., “A general method to design dominant negatives to B-HLHZip proteins that abolish DNA binding,” PNAS, vol. 94, No. 23, pp. 12274-12279 (1997).
[cited by applicant]
Kungulovski, et al., “Epigenome editing: state of the art, concepts, and perspectives,” Trends in Genetics, 32.2: 101-113 (2015).
[cited by applicant]
Lee, et al., “Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1,”
[cited by applicant]
Lei, et al., “Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein,” Nature Communications, 8, Article No. 16026 (2017).
[cited by applicant]
Li, et al., “An alternative CTCF isoform antagonizes canonical CTCF occupancy and changes chromatin architecture to promote apoptosis,” Nature Communications, article No. 1535; pp. 1-13 (2019).
[cited by applicant]
Lin, et al., “Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins” Molecular Cell, vol. 60, pp. 208-219 (2015).
[cited by applicant]
Ling, J Q, et al., “Long-range DNA interactions are specifically altered by locked nucleic acid-targeting of a CTFC binding site,” Biochimica et Biophysica Acta. Gene Regulatory Mechanisms, vol. 1809, No. 1. pp. 24-33 (…
[cited by applicant]
Liu, et al., “Editing DNA Methylation in the Mammalian Genome,” Cell, 167(1):233-247 (2016).
[cited by applicant]
Lo, et al., “Genetic and epigenetic control of gene expression by CRISPR-Cas systems,” FI000Research, 6: 747 (2017).
[cited by applicant]
Lopez-Bertoni, et al., “DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2,” Oncogene, 34, 3994-4004 (2017).
[cited by applicant]
Ma, et al. “Targeted Gene Suppression by Inducing De Novo DNA Methylation in the Gene Promotor,” Epigenetics & Chromatin, vol. 7:20, pp. 1-11 (2014).
[cited by applicant]
Mansour, M. et al., “An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element,” Science, 346(6215):1373-7 (Nov. 13, 2014).
[cited by applicant]
Martinowich, K., “DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation,” Science 302, 890-893 (2003).
[cited by applicant]
McClellan, Michael J., et al., “Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming,”
[cited by applicant]
McDonald, et al., “Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation,” Biology open, 5.6: 866-874 (2016).
[cited by applicant]
Morgan, et al., “Manipulation of nuclear architecture through CRISPR-mediated chromosomal looping,” Nature Communications, vol. 8, Article 15993, 9 pages (2017).
[cited by applicant]
Morita, et al., “Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions,” Nature biotechnology, 34.10:1060-1065 (2016).
[cited by applicant]
Narenda, et al. “CTCF establishes discrete functional chromatin domains at the Hox clusters during differentiation,” Science, vol. 347, No. 6225, pp. 1017-1021 (2015).
[cited by applicant]
Narlikar, et al., “Identifying regulatory elements in eukaryotic genomes,”
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/326,700 dated Dec. 7, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/469,131 dated Jun. 20, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/476,868 dated Jul. 6, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/476,868, mailed Jun. 1, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/476,868 dated Sep. 19, 2023.
[cited by applicant]
Patterson, et al., “DNA Methylation: Bisulphite Modification and Analysis” J Vis Exp., vol. 56, e3170, pp. 1-9 (2011).
[cited by applicant]
Phillips, J.E., et al., “CTCF: master weaver of the genome,” Cell 137, 1194-1211 (2009).
[cited by applicant]
Rada-Iglesias, et al., “Whole-genome maps of USFI and USF2 binding and histone H3 acetylation reveal new aspects of promoter structure and candidate genes for common human disorders,” Genome Research, vol. 18(3), pp. 38…
[cited by applicant]
Ran, et al., “Genome engineering using the CRISPR-Cas9 system,” Nature Protocols, vol. 8, No. 11, pp. 2281-2308, (2013).
[cited by applicant]
Rodriguez, et al., “CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus,” Biochem. Biophys. Res. Commun., 392(2):129-34, (2010).
[cited by applicant]
Rudolph Jaenish, In Vitro Reprogramming of Somatic Cells Into Pluripotent ES-Like Cells, HD045022 (Funding date: Jun. 15, 2008).
[cited by applicant]
Rudolph Jaenish, Nuclear Cloning and the Reprogramming of the Genome, HD045022 (Funding date: Jul. 28, 2003).
[cited by applicant]
Sabari, et al., “Coactivator condensation at super-enhancers links phase separation and gene control,” Science, 361(6400): eaar3958, pp. 1-16 (2018).
[cited by applicant]
Schultz, M.D., et al., “Human body epigenome maps reveal noncanonical DNA methylation variation.” Nature 523, 212-216 (2015).
[cited by applicant]
Shin, et al., “Spatiotemporal control of intracellular phase transitions using light-activated optoDroplets,” Cell, vol. 168, No. 1-2, pp. 159-171, (2017).
[cited by applicant]
Singh, et al., “Protein Engineering Approaches in the Post-Genomic Era,” Current Protein and Peptide Science, 18, 1-11 (2017).
[cited by applicant]
Spencer, R. et al., “A Boundary Element Between Tsix and Xist Binds the Chromatin Insulator Ctcf and Contributes to Initiation of X-Chromosome Inactivation,” Genetics, 189:441-454 (2011).
[cited by applicant]
Stelzer, Y., et al., “Tracing dynamic changes of DNA methylation at single-cell resolution,” Cell 163, 218-229 (2015).
[cited by applicant]
Stepper, et al., “Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase,” Nucleic acids research, 45.4: 1703-1713 (2016).
[cited by applicant]
Subramaniam, et al., “DNA methyltransferases: a novel target for prevention and therapy,” Frontiers in Oncology, 4 (May 1, 2014).
[cited by applicant]
Supplementary Partial European Search Report in Application No. EP 17 88 1835, dated Jul. 30, 2020.
[cited by applicant]
Sweatt, J.D., “The emerging field of neuroepigenetics,” Neuron 80, 624-632 (2013).
[cited by applicant]
Szabó, P. et al., “Role of CTCF Binding Sites in the Igf2/H19 Imprinting Control Region,” Molecular and Cellular Biology, 24(11):4791-4800 (2004).
[cited by applicant]
Tang, Z. et al., “CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription,” Cell, 163:1-17 (2015).
[cited by applicant]
Thakore, et al., “Highly Specific Epigenome Editing by CRISPR/Cas9 Repressors for Silencing of Distal Regulatory Elements,” Nat Methods, vol. 12, No. 12, pp. 1143-1149, (2015).
[cited by applicant]
The ENCODE Project Consortium, “An Integrated Encyclopedia of DNA Elements in the Human Genome” Nature, vol. 6; 489 (7414):57-74 (2012).
[cited by applicant]
Torres, A. et al., “Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2′-O-methyl (OMe) mixmer anti-miRs in the absence …
[cited by applicant]
Viscidi, et al., “Novel Chemical Method for the Preparation of Nucleic Acids for Nonisotopic Hybridization,” J Clin Microbiol, vol. 23, No. 2, pp. 311-317 (1986).
[cited by applicant]
Votja, et al., “Repurposing the CRISPR-Cas9 system for targeted DNA methylation,” Nucleic Acids Research, 2016, vol. 44, No. 12 5615-5628 (published on Mar. 11, 2016).
[cited by applicant]
Wang, H., et al., “Widespread plasticity in CTCF occupancy linked to DNA methylation,” Genome Res 22, 1680-1688 (2012).
[cited by applicant]
Weintraub, Abraham S., et al., “YY1 is a structural regulator of enhancer-promoter loops.”
[cited by applicant]
Woloszynska-Read, et al., “DNA Methylation-dependent Regulation of BORIS/CTCFL Expression in Ovarian Cancer,” Cancer Immunity, vol. 7, 1 pp. 1-10 (2007).
[cited by applicant]
Written Opinion for PCT/US2017/50553 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 12 pages (dated Jan. 30, 2018).
[cited by applicant]
Written Opinion for PCT/US2017/50556 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 8 pages (dated Dec. 26, 2017).
[cited by applicant]
Written Opinion for PCT/US2017/50558 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 6 pages (dated Dec. 18, 2017).
[cited by applicant]
Written Opinion for PCT/US2017/50561 (Methods and Compositions for Modulating Gene Expression, filed Sep. 7, 2017), issued by ISA/US, 6 pages (dated Dec. 18, 2017).
[cited by applicant]
Wu, et al., “MicroRNAs direct rapid deadenylation of mRNA” Proc Natl Acad Sci, vol. 103, pp. 4034-4039 (2006).
[cited by applicant]
Wu, H., et al., “Reversing DNA methylation: mechanisms, genomics, and biological functions,” Cell 156, 45-68 (2014).
[cited by applicant]
Xiong, et al. “Targeted DNA methylation in human cells using engineered dCas9-methyltransferases,” Scientific reports, 7.1: 1-14 (2017).
[cited by applicant]
Xu, et al., “A CRISPR-based approach for targeted DNA demethylation,” Cell discovery, 2.1: 1-12 (2016).
[cited by applicant]
Yan, et al., “DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment,” Oncogene, 35(30):3995-4008 (2016).
[cited by applicant]
Young, et al., Abstract, “Epigenomic Changes in Normal T-cell Development and Leukemogenesis,” National Institutes of Health Grant No. CA109901 (Funding Date: Apr. 15, 2010).
[cited by applicant]
Young, et al., Abstract, “Transcriptional Ragulatory Network in Living Cells,” National Institutes of Health Grant No. HG002668 (Funding Date: May 2, 2003).
[cited by applicant]
Zhang, et al., “Propagated Perturbations from a Peripheral Mutation Show Interactions Supporting WW Domain Thermostability,” Structure, 26, 1474-1485 (2018).
[cited by applicant]
Zhao, et al., “CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression,” Oncogene, 35, 3565-3576 (2016).
[cited by applicant]
Ziebarth, et al., “CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization,” Nucleic Acid Research, vol. 41; D188-94 (2013).
[cited by applicant]
Corrected Notice of Allowability for U.S. Appl. No. 17/858,758 mailed May 23, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/858,758 mailed Dec. 8, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/858,758 mailed Jul. 23, 2024.
[cited by applicant]
Stepper, Peter, et al. “Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase.” Nucleic acids research, 45.4 (2016): 1703-1713.
[cited by applicant]
Young et al., Abstract “Transcriptional Regulatory Networks in Living Cells,” National Institutes of Health Grant No. HG002668 (Funding Start Date: Apr. 17, 2007).
[cited by applicant]
Young et al., Abstract “Transcriptional Regulatory Networks in Living Cells,” National Institutes of Health Grant No. HG002668 (Funding Start Date: Jul. 1, 2015).
[cited by applicant]
Young et al., Abstract “Transcriptional Regulatory Networks in Living Cells,” National Institutes of Health Grant No. HG002668 (Funding Start Date: May 26, 2010).
[cited by applicant]
Zheng, “Cellular and Molecular Biology of Tumors,” Military Medical Press, pp. 265-273, 2014.
[cited by applicant]